Free Trial

Sarepta Therapeutics (SRPT) Stock Forecast & Price Target

Sarepta Therapeutics logo
$22.64 +0.29 (+1.30%)
Closing price 10/3/2025 04:00 PM Eastern
Extended Trading
$22.70 +0.05 (+0.24%)
As of 10/3/2025 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Sarepta Therapeutics - Analysts' Recommendations and Stock Price Forecast (2025)

Consensus Rating

Sell
7
Hold
14
Buy
9

Based on 30 Wall Street analysts who have issued ratings for Sarepta Therapeutics in the last 12 months, the stock has a consensus rating of "Hold." Out of the 30 analysts, 7 have given a sell rating, 14 have given a hold rating, and 9 have given a buy rating for SRPT.

Consensus Price Target

$39.32
73.67% Upside
According to the 30 analysts' twelve-month price targets for Sarepta Therapeutics, the average price target is $39.32. The highest price target for SRPT is $150.00, while the lowest price target for SRPT is $12.00. The average price target represents a forecasted upside of 73.67% from the current price of $22.64.
MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
Get the Latest News and Ratings for SRPT and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Sarepta Therapeutics and its competitors.

Sign Up
By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

SRPT Analyst Ratings Over Time

TypeCurrent Forecast
10/4/24 to 10/4/25
1 Month Ago
9/4/24 to 9/4/25
3 Months Ago
7/6/24 to 7/6/25
1 Year Ago
10/5/23 to 10/4/24
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
1 Strong Buy rating(s)
Buy
9 Buy rating(s)
8 Buy rating(s)
12 Buy rating(s)
16 Buy rating(s)
Hold
14 Hold rating(s)
15 Hold rating(s)
12 Hold rating(s)
2 Hold rating(s)
Sell
7 Sell rating(s)
6 Sell rating(s)
1 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$39.32$43.50$60.88$187.44
Forecasted Upside73.67% Upside135.64% Upside234.20% Upside55.68% Upside
Consensus RatingHoldHoldHoldModerate Buy

SRPT Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

SRPT Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Sarepta Therapeutics Stock vs. The Competition

TypeSarepta TherapeuticsMedical CompaniesS&P 500
Consensus Rating Score
2.07
2.33
2.51
Consensus RatingHoldHoldModerate Buy
Predicted Upside73.67% Upside1,395.18% Upside10.50% Upside
News Sentiment Rating
Positive News

See Recent SRPT News
Positive News
Positive News
DateBrokerageAnalystActionRatingPrice TargetReport Date
Upside/Downside
Details
9/27/2025Weiss Ratings
0 of 5 stars
 Reiterated RatingSell (D)
9/22/2025BMO Capital Markets
4 of 5 stars
UpgradeMarket PerformOutperform$50.00+186.86%
9/15/2025Guggenheim
3 of 5 stars
Reiterated RatingBuy$22.00+26.51%
9/9/2025Leerink Partners
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost TargetMarket Perform$12.00 ➝ $15.00-15.33%
8/25/2025HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell
8/20/2025Bank of America
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost TargetUnderperform$17.00-15.76%
8/15/2025Deutsche Bank Aktiengesellschaft
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost TargetSell$12.00-44.85%
8/7/2025The Goldman Sachs Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost TargetNeutral$19.00+9.05%
8/7/2025Wells Fargo & Company
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost TargetOverweight$48.00 ➝ $50.00+184.72%
7/29/2025Barclays
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeUnderweightEqual Weight$22.00+26.32%
7/29/2025William Blair
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
 Reiterated RatingOutperform
7/29/2025Morgan Stanley
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost TargetEqual Weight$15.00 ➝ $20.00+44.30%
7/29/2025Piper Sandler
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost TargetNeutral$15.00+8.23%
7/29/2025Sanford C. Bernstein
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageMarket Perform$13.00-6.20%
7/29/2025Oppenheimer
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeMarket PerformOutperform$30.00 ➝ $37.00+166.96%
7/29/2025JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeUnderweightNeutral$24.00+73.16%
7/28/2025Needham & Company LLC
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingUnderperform
7/24/2025Jefferies Financial Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower TargetBuy$40.00 ➝ $35.00+220.42%
7/22/2025Citigroup
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageSell
7/21/2025UBS Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuyNeutral
7/21/2025Mizuho
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingOutperformNeutral$40.00 ➝ $14.00-0.50%
7/18/2025Leerink Partnrs
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
 DowngradeStrong-BuyHold
7/18/2025Baird R W
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
 DowngradeStrong-BuyHold
7/17/2025Royal Bank Of Canada
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower TargetSector Perform$25.00 ➝ $23.00+7.19%
7/17/2025Robert W. Baird
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost TargetOutperform$30.00 ➝ $35.00+90.42%
6/18/2025TD Cowen
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeBuyHold$24.00+11.32%
6/17/2025Wolfe Research
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoveragePeer Perform
6/16/2025Cantor Fitzgerald
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingOverweightNeutral
6/6/2025Scotiabank
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeSector PerformSector Outperform$80.00+104.03%
5/8/2025Evercore ISI
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeOutperformInline$50.00+36.17%
10/10/2024Raymond James Financial
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingOutperform$150.00+27.61%
2/29/2024Wedbush
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
 Reiterated RatingOutperform$224.00+71.29%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Saturday at 07:40 AM ET.


SRPT Forecast - Frequently Asked Questions

According to the research reports of 30 Wall Street equities research analysts, the average twelve-month stock price forecast for Sarepta Therapeutics is $39.32, with a high forecast of $150.00 and a low forecast of $12.00.

30 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Sarepta Therapeutics in the last twelve months. There are currently 7 sell ratings, 14 hold ratings and 9 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" SRPT shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in SRPT, but not buy additional shares or sell existing shares.

According to analysts, Sarepta Therapeutics's stock has a predicted upside of 73.67% based on their 12-month stock forecasts.

Over the previous 90 days, Sarepta Therapeutics's stock had 5 downgrades and 4 upgrades by analysts.

Analysts like Sarepta Therapeutics less than other "medical" companies. The consensus rating score for Sarepta Therapeutics is 2.07 while the average consensus rating score for "medical" companies is 2.33. Learn more on how SRPT compares to other companies.


This page (NASDAQ:SRPT) was last updated on 10/4/2025 by MarketBeat.com Staff
From Our Partners